myelodysplastic syndromes (MDS) is a $3.5b market and Syntara only need to contribute 700k, more importantly it go straight into Phase 2 later this year.
This is substantially more commercialized focus and less time consuming than the previous myelofibrosis trails.
Not sure how long it'll take before the market realize this.
Ann: SNT to Trial New Cancer Indication Following MRFF Grant, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
-0.001(1.72%) |
Mkt cap ! $92.76M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 5.9¢ | 5.7¢ | $67.63K | 1.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 261071 | 5.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 360185 | 2 |
View Market Depth
| Last trade - 15.59pm 07/08/2025 (20 minute delay) ? |
| SNT (ASX) Chart |